Written by Terry Grimmond
04 Feb 2020

Trustworthy Facts on 2019-nCoV and COVID-19 Waste Handling – An Update

Updated: Feburary 13th, 2020.

It's important that our customers have clear guidelines for managing waste that has been in contact with Coronavirus patients. We engaged Expert Microbiologist Terry Grimmond to provide up-to-date facts and distill waste handling recommendations.

 

The World Health Organization (WHO) states the new coronavirus 2019-nCoV outbreak has prompted an “overabundance of information” and trustworthy sources are essential for instituting evidence-based prevention measures as some information is not accurate.1 Trustworthy up-to-date sources relevant to U.S. (in addition to state and federal regulations) are WHO, and the U.S. Dept of Labour Occupational Safety and Health Administration (OSHA),andthe U.S. Centers for Disease Control and Prevention (CDC). The following advice is extracted from these and other trustworthy sources.

 

What is 2019-nCoV?

Coronaviruses are a family of seven viruses common in many animals, including camels, cattle, cats, and bats.2 Common human coronaviruses usually cause mild to moderate upper-respiratory tract illnesses, like the common cold. However, rarely, animal coronaviruses can infect people and then spread between people such as with Middle East Respiratory Syndrome (MERS),3 Severe acute respiratory syndrome (SARS),4 and now 2019-nCoV in Dec 2019.5

Note. A proposal to rename2019-nCov virus as SARS-CoV-26 has yet to be sanctioned by WHO and is not adopted at the moment. On Feb 11, WHO named the disease COVID-19.7

Symptoms of COVID-19 infection may appear between 2 to 14 days after exposure and can include fever, cough and shortness of breath, however in some of cases the illness can be severe and fatal.8

 

World and U.S. situation

By Feb 12, 2020, 45,171 cases of COVID-19 from 25 countries had been reported to WHO (44,730 cases (99.1%) in China).9 Severe illness occurred in 18% with 1,115 deaths (fatality rate 2.4% within China; 0.2% outside China).1a The fatality rate in China may be falsely high as the number of COVID-19 cases may be much larger than that reported. The U.S. has reported 14 cases and no deaths. No new countries reported COVID-19 in last 6 days.9

CDC state COVID-19 is not currently spreading in the U.S. and the immediate health risk to the general American public is low.5

Note. To put COVID-19 into perspective, U.S. has had 14 COVID-19 cases and no deaths. When compared to the current flu season, CDC estimates U.S. has had 22,000,000 flu cases with 210,000 hospitalizations (11%) and 12,000 deaths (0.6% fatality).10

 

Mode of Transmission

On current evidence, CDC state spread from person-to-person is most likely among close contacts (about 6 feet) mainly via respiratory droplets produced when an infected person coughs or sneezes.11 These droplets can land in the mouths or noses of nearby people or possibly be inhaled into their lungs. The risk of transmission from touching a contaminated surface or object is currently unclear.11

 

How “Infectious” is 2019-nCoV?

Infectivity is calculated mathematically and termed “R0” (“R-naught”) which is the number of new cases likely to occur from each case. WHO state COVID-19 R0 is likely between 1.4-2.5,7 and the upper limit is similar to the R0 of 3 for SARS,8 but less infectious than the upper limit of 1.0-5.7 for MERS.By comparison influenza is 1.3 (Seasonal) to 1.8 (Pandemic) and measles R0 is 12-18.10 At a current mortality rate of 2%,1 nCoV is considerably less fatal than SARS (11%),8 and MERS (35%).9

 

How can HCP protect themselves against 2019-nCoV?

Clear updated guidelines for healthcare professionals (HCP) protection are available at WHO,15 OSHA16 and CDC.12 CDC advises that administrative rules and engineering controls, environmental hygiene, correct work practices, and appropriate use of personal protective equipment (PPE) are all necessary to prevent infections, and all HCP who enter the room of a patient with suspected or confirmed COVID-19 should adhere to Standard, Contact, and Airborne Precautions, which along with hand hygiene may include gloves, gowns, respiratory and eye protection.12

 

How is 2019-nCoV waste handled?

OSHA, CDC and WHO all state that waste from COVID-19 patients is handled as standard regulated medical waste (RMW).12,15,16

In their 2019-nCoV Infection Prevention Recommendations, CDC state, “Management of …. medical waste should also be performed in accordance with routine procedures”,6 and refers readers to the RMW chapter of their 2003 Environmental Infection Control Guidelines.17  

For COVID-19 waste containment onsite, the RMW Guidelines state:

  • A single, leak-resistant biohazard bag is usually adequate for containment of regulated medical wastes, provided the bag is sturdy and the waste can be discarded without contaminating the bag’s exterior.
  • Contamination or puncturing of the bag requires placement into a second biohazard bag.
  • All bags should be securely closed for disposal.  

 

For transport of COVID-19 waste offsite the US Dept of Transport RMW 49 CFR 49 173.134(c) requires the above RMW plastic bags be contained in a rigid container,18 and 49 CFR 172.10119 requires it be transported as “UN 3291 Regulated medical waste, n.o.s. or Clinical waste, unspecified, n.o.s. or (BIO) Medical waste, n.o.s., or Biomedical waste, n.o.s. or Medical waste, n.o.s.” (i.e. standard RMW transport packaging).

Note. Specimens from suspect 2019-nCoV cases and cultures of 2019-nCoV are Category B substances and must be packaged and transported as UN 3373 when sent offsite.20

 

How is 2019-nCoV waste treated?

As 2019-nCoV waste is standard regulated medical waste, the RMW chapter of the CDC 2003 Environmental Infection Control Guidelines17 states:

  • Regulated medical wastes are treated or decontaminated to reduce the microbial load in or on the waste and to render the by-products safe for further handling and disposal.
  • The treatment need not render the waste “sterile”
  • Treatment processes are licensed under each state’s medical waste regulations and treatment methods may include autoclaving, incineration, chemical disinfection, grinding/shredding/disinfection methods, energy-based technologies (e.g., microwave or radiowave treatments), and disinfection/encapsulation method

 

Can reusable sharps containers be used for 2019-nCoV wastes?

Yes. 2019-nCoV is classified as RMW and reusable sharps bins may be used provided the sharps container:

 

(i) The sharps container is specifically approved and certified by the U.S. Food and Drug Administration as a medical device for reuse.

(ii) The sharps container must be permanently marked for reuse.

(iii) The sharps container must be disinfected prior to reuse by any means effective for the infectious substance the container previously contained.

(iv) The sharps container must have a capacity greater than 7.57 L (2 gallons) and not greater than 151.42 L (40 gallons) in volume.

 

Note 1. WHO states preliminary information suggests the virus may survive a few hours on surfaces and that simple disinfectants can kill the virus.26

Note 2. Reusable sharps bins are not “patient equipment” and decontamination before removing from COVID-19patient room is not required (i.e. no special handling, labelling or procedures are required).

Note 3. Under CDC 2019-nCoV Infection Prevention recommendations, all people entering patient rooms (e.g. to exchange reusable sharps containers) are required to wear PPE appropriate to the activity in the room as per facility protocols.6

 

Can reusable RMW bins be used for COVID-19 wastes?

Yes. COVID-19 wastes are classified as RMW and reusable RMW bins may be used provided the bins meet the usual requirements i.e.:

 

Downloadable PDF Version of this Blog

 

 

 

References

Novel Coronavirus (2019-nCoV). Situation Reports – 13 (Feb 2, 2020) World Health Organization. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed Feb 13, 2020.

2Coronaviruses – Symptoms and Diagnosis. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/about/symptoms.html. Accessed Feb 13, 2020.

3WHO MERS-CoV Global Summary and Assessment of Risk, July 2019 (WHO/MERS/RA/19.1). Geneva, Switzerland: World Health Organization; 2019. https://apps.who.int/iris/bitstream/handle/10665/326126/WHO-MERS-RA-19.1-eng.pdf?ua=1. Accessed Feb 13, 2020.

4Consensus document on the epidemiology of severe acute respiratory syndrome (SARS). World Health Organization. https://www.who.int/csr/sars/en/WHOconsensus.pdf. Accessed Feb 3, 2020.

52019 Novel Coronavirus (2019-nCoV) Situation Summary. Feb 7, 2020. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-nCoV/summary.html. Accessed Feb 3, 2020.

6Gorbalenya A. Severe acute respiratory syndrome-related coronavirus – The species and its viruses, a statement of the Coronavirus Study Group. Coronavirus Study Group (CSG), International Committee on Taxonomy of Viruses. bioRxiv 2020.02.07.937862. https://doi.org/10.1101/2020.02.07.937862. Accessed Feb 12, 2020.

7Novel Coronavirus (2019-nCoV). Situation Reports – 22 (Feb 11, 2020) World Health Organization. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2.  Accessed Feb 13, 2020.

8About 2019-nCoV: Symptoms. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/about/symptoms.html.  Accessed Feb 13, 2020.

9Novel Coronavirus (2019-nCoV). Situation Reports – 23 (Feb 12, 2020) World Health Organization. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200212-sitrep-23-ncov.pdf?sfvrsn=41e9fb78_2.  Accessed Feb 13, 2020.

10Weekly U.S. Influenza Surveillance Report. Centers for Disease Control and Prevention https://www.cdc.gov/flu/weekly/index.htm. Accessed Feb 13, 2020.

11How 2019-nCoV Spreads. Feb 5, 2020. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/about/transmission.html. Accessed Feb 13, 2020.

12Interim Infection Prevention and Control Recommendations for Patients with Known or Patients Under Investigation for 2019 Novel Coronavirus (2019-nCoV) in a Healthcare Setting. Feb 12, 2020. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-nCoV/hcp/infection-control.html. Accessed Feb 13, 2020.

13WHO MERS-CoV Global Summary and Assessment of Risk, July 2019 (WHO/MERS/RA/19.1). Geneva, Switzerland: World Health Organization; 2019. https://apps.who.int/iris/bitstream/handle/10665/326126/WHO-MERS-RA-19.1-eng.pdf?ua=1. Accessed Feb 13, 2020.

14Biggerstaff M, Cauchemez S, Reed C, Gambhir M, Finelli L. Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature. Centers for Disease Control and Prevention. BMC Infect Dis. BMC Infectious Diseases 2014, 14:480. http://www.biomedcentral.com/1471-2334/14/480. Accessed Feb 13, 2020.

15Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected: interim guidance. World Health Organization. https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125. Accessed Feb 13, 2020.

16Occupational Safety and Health Administration 2019 Novel Coronavirus. https://www.osha.gov/SLTC/novel_coronavirus/controlprevention.html. Accessed Feb 13, 2020.

17Regulated Medical Waste, Chapter I, Part 1 of Guidelines for Environmental Infection Control in Health-Care Facilities (2003) Updated: July 2019. https://www.cdc.gov/infectioncontrol/guidelines/environmental/background/medical-waste.html. Accessed Feb 13, 2020.

1849 CFR 173.134(c) – Exceptions for regulated medical waste. US Department of Transportation. https://www.law.cornell.edu/cfr/text/49/173.197. Accessed Feb 13, 2020.

1949 CFR 172.101 Hazardous Materials Table. US Department of Transportation. https://www.ecfr.gov/cgi-bin/text-idx?SID=ae15ede2730beed1bb677b2021049803&mc=true&node=se49.2.172_1101&rgn=div8. Accessed Feb 13, 2020.

20Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with 2019 Novel Coronavirus (2019-nCoV). Feb 10, 2020. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Flab-biosafety-guidelines.html  Accessed Feb 13, 2020.

2129 CFR 1910.1-30. OSHA Bloodborne Pathogens Standard. https://www.osha.gov/pls/oshaweb/owadisp.show_document?p_id=10051&p_table=STANDARDS. Accessed Feb 13, 2020.

22Guidance on the content and format of premarket notification [510(k)] submissions for sharps containers. Infection Control Devices Branch, Office of Device Evaluation, US Food and drug Administration. https://www.fda.gov/media/72328/download. Accessed Feb 13, 2020.

2349 CFR § 173.134 - Class 6, Division 6.2 - Definitions and exceptions. US Department of Transportation. https://www.law.cornell.edu/cfr/text/49/173.134. Accessed Feb 13, 2020.

24Regulated Medical Waste: Sharps. 49 CFR 173.197(e)(3). US Department of Transportation. US Department of Transportation. https://www.law.cornell.edu/cfr/text/49/173.197. Accessed Feb 13, 2020.

25State-by-State Regulated Medical Waste Resource Locator. Healthcare Environmental Resource Center (HERC). http://www.hercenter.org/rmw/rmwlocator.php. Accessed Feb 13, 2020.

26How long does the virus survive on surfaces? WHO Q&A on Coronaviruses. Feb 2, 2020. World Health Organization. https://www.who.int/news-room/q-a-detail/q-a-coronaviruses. Accessed Feb 13, 2020.

 

Header Style: 
Terry Grimmond

Terry Grimmond

Consultant Microbiologist

Terry Grimmond, a consultant microbiologist with 50 years experience, lead investigator on US ExpoStop annual survey, active researcher and a zealous advocate who has spoken at 190 conferences in 22 countries